<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890084</url>
  </required_header>
  <id_info>
    <org_study_id>502.581</org_study_id>
    <nct_id>NCT00890084</nct_id>
  </id_info>
  <brief_title>Telmisartan Tab Hypertension</brief_title>
  <official_title>RESPECT: Observational, Prospective, Open-label, Multi-center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Blood Pressure &lt; 140/90 mm Hg</measure>
    <time_frame>12 weeks</time_frame>
    <description>% of high risk patients with Blood Pressure &lt; 140/90 mm Hg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Blood Pressure &lt; 130/80 mm Hg</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Blood Pressure Decrease</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Response Rate (Drop of Systolic BP of 10mmHg or More)</measure>
    <time_frame>12 weeks</time_frame>
    <description>BP response rate (drop of systolic BP of ≥ 10mmHg) after approximately 12 weeks of treatment with telmisartan (alone or in fixed combination with HCTZ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Patterns</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment patterns observed at the end of the study as Micardis monotherapy, Micardis Plus 12.5 and Micardis Plus 25 (with or without changes in concomitant antihypertensive medications).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Concomitant Antihypertensive Drugs Given at Study Entry</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Percentage of patients who had a change in concomitant antihypertensive drugs prescribed at initiation and after 12 weeks. The antihypertensive drugs were changed (which is stopped, titration of dose and started) or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to &lt; 130/80 mm Hg</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure should be reduced to at least below 140/90 mm Hg (systolic/diastolic),and to lower values, if tolerated, in all hypertensive patients. Target blood pressure should be lower than 130/80 mmHg in diabetics and in high or very high risk patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2913</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</intervention_name>
    <description>Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg</description>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk
        according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision
        to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12.5 mg or 25 mg, in
        the usual way and in line with the SmPC and reimbursement criteria

        Exclusion criteria:

        Contra-indications as in the Summary of Product Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Luxembourg</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <results_first_submitted>December 30, 2011</results_first_submitted>
  <results_first_submitted_qc>April 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2012</results_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>April 1st 2009 to January 1st 2010 recruited in 90.5% General Practitioners (GP's) and 9.5% Specialists (Sp's)</recruitment_details>
      <pre_assignment_details>45 patients excluded for inclusion/exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2913"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2771"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2913"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic and diastolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.9" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Blood Pressure &lt; 140/90 mm Hg</title>
        <description>% of high risk patients with Blood Pressure &lt; 140/90 mm Hg</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Blood Pressure &lt; 140/90 mm Hg</title>
          <description>% of high risk patients with Blood Pressure &lt; 140/90 mm Hg</description>
          <population>Intention-to-Treat (ITT)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="67.9" upper_limit="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Blood Pressure &lt; 130/80 mm Hg</title>
        <time_frame>12 weeks</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Blood Pressure &lt; 130/80 mm Hg</title>
          <population>Intention to Treat (ITT)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="12.0" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Blood Pressure Decrease</title>
        <description>systolic blood pressure</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Blood Pressure Decrease</title>
          <description>systolic blood pressure</description>
          <population>Intention to treat (ITT)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="22.7" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Response Rate (Drop of Systolic BP of 10mmHg or More)</title>
        <description>BP response rate (drop of systolic BP of ≥ 10mmHg) after approximately 12 weeks of treatment with telmisartan (alone or in fixed combination with HCTZ)</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>BP Response Rate (Drop of Systolic BP of 10mmHg or More)</title>
          <description>BP response rate (drop of systolic BP of ≥ 10mmHg) after approximately 12 weeks of treatment with telmisartan (alone or in fixed combination with HCTZ)</description>
          <population>ITT Population</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.85" lower_limit="90.8" upper_limit="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Patterns</title>
        <description>Treatment patterns observed at the end of the study as Micardis monotherapy, Micardis Plus 12.5 and Micardis Plus 25 (with or without changes in concomitant antihypertensive medications).</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Patterns</title>
          <description>Treatment patterns observed at the end of the study as Micardis monotherapy, Micardis Plus 12.5 and Micardis Plus 25 (with or without changes in concomitant antihypertensive medications).</description>
          <population>ITT Population</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Telmisartan 40mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telmisartan 80mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telmisartan 40/12,5mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telmisartan 80/12,5mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telmisartan 80/25mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Concomitant Antihypertensive Drugs Given at Study Entry</title>
        <description>Percentage of patients who had a change in concomitant antihypertensive drugs prescribed at initiation and after 12 weeks. The antihypertensive drugs were changed (which is stopped, titration of dose and started) or not.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Concomitant Antihypertensive Drugs Given at Study Entry</title>
          <description>Percentage of patients who had a change in concomitant antihypertensive drugs prescribed at initiation and after 12 weeks. The antihypertensive drugs were changed (which is stopped, titration of dose and started) or not.</description>
          <population>Intention to treat (ITT)</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="12.3" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to &lt; 130/80 mm Hg</title>
        <time_frame>12 weeks</time_frame>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to &lt; 130/80 mm Hg</title>
          <population>Intention to treat (ITT)</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="10.5" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007</title>
        <description>Blood pressure should be reduced to at least below 140/90 mm Hg (systolic/diastolic),and to lower values, if tolerated, in all hypertensive patients. Target blood pressure should be lower than 130/80 mmHg in diabetics and in high or very high risk patients</description>
        <time_frame>12 weeks</time_frame>
        <population>all investigators participating in the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007</title>
          <description>Blood pressure should be reduced to at least below 140/90 mm Hg (systolic/diastolic),and to lower values, if tolerated, in all hypertensive patients. Target blood pressure should be lower than 130/80 mmHg in diabetics and in high or very high risk patients</description>
          <population>all investigators participating in the trial</population>
          <units>percentage of prescribers</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="43" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>solicited reporting</desc>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2771"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2771"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2771"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral hemorrhage, fatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2771"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2771"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

